Evidence supporting the multiple clinical benefits of SGLT2 inhibitors and GLP-1 receptor agonists has outpaced their effective implementation in clinical practice, according to the American Heart Association. An AHA scientific statement, Cardiorenal Protection With the Newer Antidiabetic Agents in Patients With Diabetes and Chronic Kidney Disease, said the antihyperglycaemic agents are typically only initiated by ...
Cardiologist collaboration required for patients to get cardiorenal benefit of SGLT2i
By Mardi Chapman
29 Sep 2020